191 related articles for article (PubMed ID: 38493215)
1. Axl and MerTK regulate synovial inflammation and are modulated by IL-6 inhibition in rheumatoid arthritis.
Nerviani A; Boutet MA; Ghirardi GM; Goldmann K; Sciacca E; Rivellese F; Pontarini E; Prediletto E; Abatecola F; Caliste M; Pagani S; Mauro D; Bellan M; Cubuk C; Lau R; Church SE; Hudson BM; Humby F; Bombardieri M; Lewis MJ; Pitzalis C
Nat Commun; 2024 Mar; 15(1):2398. PubMed ID: 38493215
[TBL] [Abstract][Full Text] [Related]
2. The level of synovial AXL expression determines the outcome of inflammatory arthritis, possibly depending on the upstream role of TGF-β1.
Waterborg CEJ; Broeren MGA; Blaney Davidson EN; Koenders MI; van Lent PLEM; van den Berg WB; van der Kraan PM; van de Loo FAJ
Rheumatology (Oxford); 2019 Mar; 58(3):536-546. PubMed ID: 30508140
[TBL] [Abstract][Full Text] [Related]
3. Tyro3/Axl/Mertk-deficient mice develop bone marrow edema which is an early pathological marker in rheumatoid arthritis.
Waterborg CEJ; Koenders MI; van Lent PLEM; van der Kraan PM; van de Loo FAJ
PLoS One; 2018; 13(10):e0205902. PubMed ID: 30335822
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of lung homeostasis and silicosis by the TAM receptors MerTk and Axl.
Guimarães-Pinto K; Leandro M; Corrêa A; Maia EP; Rodrigues L; da Costa ALA; Rafael Machado Ferreira J; Claudio-Etienne E; Siebenlist U; He J; Rigoni TDS; Ferreira TPT; Jannini-Sa YAP; Matos-Guedes HL; Costa-da-Silva AC; Lopes MF; Silva PMR; Kelsall BL; Filardy AA
Front Immunol; 2024; 15():1380628. PubMed ID: 38774866
[TBL] [Abstract][Full Text] [Related]
6. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
7. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.
DeBerge M; Glinton K; Subramanian M; Wilsbacher LD; Rothlin CV; Tabas I; Thorp EB
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33529176
[TBL] [Abstract][Full Text] [Related]
8. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis.
Pagani S; Bellan M; Mauro D; Castello LM; Avanzi GC; Lewis MJ; Sainaghi PP; Pitzalis C; Nerviani A
Dis Markers; 2020; 2020():1614627. PubMed ID: 32051695
[TBL] [Abstract][Full Text] [Related]
10. Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers.
Grabiec AM; Goenka A; Fife ME; Fujimori T; Hussell T
Eur J Immunol; 2018 May; 48(5):855-860. PubMed ID: 29400409
[TBL] [Abstract][Full Text] [Related]
11. Increased Mer and Axl receptor tyrosine kinase expression on glomeruli in lupus nephritis.
Li S; Guo Q; Zhu H; Li Z; Su Y; Dong B
Clin Rheumatol; 2017 May; 36(5):1063-1070. PubMed ID: 28127639
[TBL] [Abstract][Full Text] [Related]
12. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
13. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway.
O'Donnell K; Harkes IC; Dougherty L; Wicks IP
Am J Pathol; 1999 Apr; 154(4):1171-80. PubMed ID: 10233855
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.
Evans AL; Blackburn JWD; Taruc K; Kipp A; Dirk BS; Hunt NR; Barr SD; Dikeakos JD; Heit B
Mol Biol Evol; 2017 Jul; 34(7):1613-1628. PubMed ID: 28369510
[TBL] [Abstract][Full Text] [Related]
15. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
16. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis.
van den Brand BT; Abdollahi-Roodsaz S; Vermeij EA; Bennink MB; Arntz OJ; Rothlin CV; van den Berg WB; van de Loo FA
Arthritis Rheum; 2013 Mar; 65(3):671-80. PubMed ID: 23203851
[TBL] [Abstract][Full Text] [Related]
18. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
19. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D; Graham DK; Wang X
J Med Chem; 2024 Apr; 67(7):5866-5882. PubMed ID: 38556760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
